A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab Combined with Alemtuzumab as Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Older Patients: A Trial of the ECOG-ACRIN Cancer Research Group (E1908)

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) patients requiring initial therapy are often older and frailer and unsuitable candidates for standard chemoimmunotherapy regimens. Shorter duration combination monoclonal antibody (mAb) therapy using alemtuzumab and rituximab has been sho...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Am J Hematol
Asıl Yazarlar: Zent, Clive S., Wang, Xin Victoria, Ketterling, Rhett P., Hanson, Curtis A., Libby, Edward N., Barrientos, Jacqueline C., Call, Timothy G., Chang, Julie E., Liu, Jane J., Calvo, Alejandro R., Lazarus, Hillard M., Rowe, Jacob M., Luger, Selina M., Litzow, Mark R., Tallman, Martin S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2016
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4806550/
https://ncbi.nlm.nih.gov/pubmed/26662208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24265
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller